Corvus Pharmaceuticals, Inc.
CRVS
Positions held
Your positionsCRVS isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Corvus Pharmaceuticals operates in the biotechnology sector, which is known for its potential to deliver groundbreaking therapies and treatments, attracting significant investor interest.
- Corvus Pharmaceuticals has a market capitalization of approximately $888 million, indicating a substantial valuation in the biotech space.
- The company's target mean price is $33.14, suggesting a significant upside potential from its current trading levels.
- The company has reported zero revenue for multiple quarters, indicating a lack of product sales and commercial viability.
- Corvus Pharmaceuticals has a negative profit margin of 0%, reflecting ongoing financial losses without any income generation.
- The company's net income for the most recent quarter was -$17.96 million, continuing a trend of increasing losses over the past several quarters.
Fundamentals
| Market cap | $858.87M | Enterprise value | $644.37M | Trailing P/E | — | Forward P/E | -9.56 |
| PEG | — | Price / book | 3.81 | Beta | 1.43 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -35.4% | ROA | -21.7% | Debt / equity | 0.00 |
| Current ratio | 16.16 | Free cash flow | -$27.40M | Analyst recommendation | strong_buy | Mean target | $33.14 |
| 52w high | $26.95 | 52w low | $6.39 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$18.0M | -$13.7M | -$12.3M | -$10.2M | -$8.0M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$19.3M | -$14.9M | -$12.2M | -$10.6M | -$10.3M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$15.3M | -$62.3M | -$27.0M | -$41.3M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$43.0M | -$27.5M | -$23.4M | -$32.6M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-25 · Corvus Pharmaceuticals (CRVS) Faces A Valuation Test, Is The Upside Already Priced In?
2026-09-03 · Corvus Pharmaceuticals to Present at the 2026 Cantor Global Healthcare Conference
2026-08-17 · Corvus Pharmaceuticals (CRVS): This Clinical-Stage Drugmaker Just Got A Lot More Interesting
2026-08-14 · Corvus Pharmaceuticals (CRVS) Q2 2026 Earnings Call Transcript
2026-08-07 · Corvus Pharmaceuticals Inc (CRVS) (Q2 2026) Earnings Call Highlights: Advancing Soquelitinib ...
2026-08-07 · Corvus Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
2026-08-07 · Corvus Pharmaceuticals Q2 Earnings Call Highlights
2026-08-06 · Corvus: Q2 Earnings Snapshot
2026-08-06 · Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results
2026-07-30 · Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026
Price (daily)
Full chart · RSI · MACD · patterns